ScreenerHero

SNOA Sonoma Pharmaceuticals, Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · sonomapharma.com
1.160USD-4.92%Mkt Cap: 5.55M $P/E: —

Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United State…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.13BUSDP/E 24.9
TAK
Takeda Pharmaceutical Company Limited
$59.16BUSD
TEVA
Teva Pharmaceutical Industries Limited
$45.78BUSDP/E 65.4
GALD
Galderma Group AG
$43.33BUSDP/E 56.1
HLN
Haleon plc
$40.72BUSDP/E 18.9
SDZ
Sandoz Group AG
$34.23BUSDP/E 59.2
HLN
Haleon plc
$32.92BUSDP/E 19.1
ZTS
Zoetis Inc.
$30.20BUSDP/E 12.0
UTHR
United Therapeutics Corporation
$22.85BUSDP/E 19.1
VTRS
Viatris Inc.
$20.03BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.06BUSDP/E 110.0
NBIX
Neurocrine Biosciences, Inc.
$14.36BUSDP/E 20.7
IPN
Ipsen S.A.
$12.68BUSDP/E 22.9
ELAN
Elanco Animal Health Incorporated
$11.26BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.16BUSDP/E 27.7
KRK
Krka, d. d.
$8.71BUSDP/E 19.4
AMRX
Amneal Pharmaceuticals, Inc.
$6.84BUSDP/E 40.1
HLUN-B
H. Lundbeck A/S
$6.66BUSDP/E 11.8
ALKS
Alkermes plc
$6.73BUSDP/E 105.6
HIMS
Hims & Hers Health, Inc.
$6.55BUSD

Key Statistics

Company
Market Cap5.55M USD
Enterprise Value1.29M USD
Revenue (TTM)21.92M USD
Gross Profit7.42M USD
Net Income (TTM)-3.17M USD
Revenue/Share9.81 USD
Last Price1.160 USD
Fiscal Year EndMar 2026
MR QuarterJun 2026
Employees10
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.20
PEG1.08
EV/EBITDA-1.02
EV/Revenue0.06
P/S0.27
P/B0.72
EPS (TTM)-1.20
EPS (Forward)-0.56
52W Range
0.85008% of range4.600
52W High4.600 USD
52W Low0.8500 USD
Profitability
Gross Margin37.97%
Oper. Margin-0.62%
EBITDA Margin-5.80%
Profit Margin-16.26%
ROE-102.58%
ROA-22.74%
Growth
Revenue Growth59.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.93M USD
CapEx (TTM)192.00K USD
FCF Margin-6.71%
FCF Yield-26.46%
Net Debt-4.60M USD
Net Debt/EBITDA3.62
Balance Sheet
Debt/Equity0.27
Current Ratio2.99
Quick Ratio1.56
Book Value/Sh1.72 USD
Cash/Share1.11 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJun 20, 2019
Splits
Last Split1:20
Split DateAug 30, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.4.79M
Float4.77M
Insiders0.42%
Institutions2.31%
Short Interest
Short Ratio3.2d
Short % Float4.23%
Short % Out.4.21%
Shares Short201.49K
Short (prev mo.)201.05K
Technical
SMA 501.276 (-9.1%)
SMA 2001.925 (-39.7%)
Beta1.30
S&P 52W Chg16.45%
Avg Vol (30d)57.53K
Avg Vol (10d)41.82K
Technical Indicators
RSI (14)36.3
MACD-0.0197
MACD Signal-0.0090
MACD Hist.-0.0107
BB Upper1.340 USD
BB Middle1.260 USD
BB Lower1.181 USD
BB Width12.63%
ATR (14)0.0602 USD
Vol Ratio (20d)1.83x